跳至主要内容
临床试验/NCT02900209
NCT02900209已完成不适用

Responses of the Immune System to Influenza Vaccination in Phenotypes of Chronic Obstructive Pulmonary Disease

University of Lincoln2 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2016年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
54
试验地点
2
主要终点
Haemagglutination inhibition (HI) antibody titres

研究概览

简要总结

The aim of this study is to determine responses of the immune system to the annual flu vaccination in people with COPD who experience frequent or infrequent exacerbations and healthy participants. We will collect blood and saliva immediately before and one month after flu vaccination at GP surgeries in the Autumn/Winter period. By measuring how quickly antibodies (that provide protection against infection) develop in the blood after vaccination we can provide important new information to help confirm whether those prone to COPD flare ups have weaker immune systems.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
65 Years 至 85 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 65-85 years with a diagnosis of COPD (according to Global Initiative for Chronic Obstructive Lung Disease criteria: post bronchodilator FEV1/FVC ratio <0.70) and moderate to severe airflow limitation (FEV1 30-80% predicted) who opt to receive the annual influenza vaccine.
  • We will also include healthy participants aged 65-85 years without symptoms of lung disease who opt to receive the annual influenza vaccine.

排除标准

  • Unable/unwilling to provide informed consent
  • Any history of allergies, suspected hypersensitivity and/or contraindication to vaccines (e.g egg protein allergy)
  • Participation in another clinical trial (use of investigational product or device)
  • Not on optimal treatment (COPD patients only)
  • Current smokers, exhaled CO >10 parts per million
  • Clinical instability, defined as experiencing a COPD exacerbation less than 4 weeks prior to baseline visit, as indicated by treatment with systemic glucocorticosteroids and/or antibiotics and/or hospitalization (COPD only)
  • An upper/lower respiratory tract infection e.g. common cold, sinus symptoms, pneumonia, which has not resolved four weeks prior to baseline visit
  • Diagnosis of asthma and/or other relevant lung disease (e.g. history of primary or clinically significant bronchiectases, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease [e.g. fibrosis, silicosis, sarcoidosis], active tuberculosis)
  • Known alpha-1-antitrypsin deficiency
  • Immunological diseases or known infection with Human Immunodeficiency Virus (HIV)
  • Any diagnosis of a malignant disease (other than basal or squamous cell carcinoma) in the last 5 years
  • Currently taking immunosuppressive medications
  • Diagnosis of diabetes mellitus
  • Severe renal failure (calculated eGFR less than 60 ml/min)
  • Liver impairment Child-Pugh B/C and/or active viral hepatitis
  • Severe psychiatric or neurological disorders (Parkinson's disease or motor neurone disease)
  • Planned donation of human tissue (blood, organs or bone marrow) during the course of the trial

结局指标

主要结局

Haemagglutination inhibition (HI) antibody titres

时间窗: October 2016 - August 2017

次要结局

  • Pseudotype-based neutralization antibody titres(October 2016 - August 2017)
  • Serum and saliva concentrations of total (and sub-classes of) IgA, IgG and IgM(October 2016 - August 2017)
  • Concentrations of inflammatory mediators in RNA extracted from unstimulated and in vitro stimulated peripheral blood mononuclear cells.(October 2016 - August 2017)
  • Plasma concentrations of markers of B and T cell activation(October 2016 - August 2017)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Arwel Jones

Research Fellow

University of Lincoln

研究点 (2)

Loading locations...

相似试验